UK Markets closed

Hikma Pharmaceuticals PLC (HIK.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
2,547.00+3.00 (+0.12%)
At close: 4:35PM GMT
Full screen
Previous close2,544.00
Open2,556.00
Bid2,550.00 x 0
Ask2,550.00 x 0
Day's range2,546.00 - 2,601.00
52-week range1,596.00 - 2,768.00
Volume391,360
Avg. volume598,156
Market cap5.871B
Beta (5Y monthly)0.05
PE ratio (TTM)12.07
EPS (TTM)211.10
Earnings date25 Feb 2021 - 01 Mar 2021
Forward dividend & yield0.24 (0.94%)
Ex-dividend date20 Aug 2020
1y target est23.92
  • Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineum™ in the Middle East and North Africa
    Business Wire

    Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineum™ in the Middle East and North Africa

    Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceuticals, a multi-national pharmaceutical company and leading licensing partner in the Middle East and North Africa ("MENA") region specializing in the development and commercialization of a broad range of high-quality medicines, today announced that the companies have entered into an exclusive licensing agreement for the registration and commercialization of Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer ("NMIBC") and other types of cancer in MENA. Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive NMIBC. In December 2019, the Company initiated the BLA submission for Vicineum to the FDA under Rolling Review.

  • Amarin vs. the Generics: Who Will Win?
    Motley Fool

    Amarin vs. the Generics: Who Will Win?

    After Amarin lost its patent rights in the U.S., the stock crashed overnight. Investors might want to stay optimistic.

  • Can MGE Energy, Inc. (NASDAQ:MGEE) Performance Keep Up Given Its Mixed Bag Of Fundamentals?
    Simply Wall St.

    Can MGE Energy, Inc. (NASDAQ:MGEE) Performance Keep Up Given Its Mixed Bag Of Fundamentals?

    MGE Energy's (NASDAQ:MGEE) stock is up by 7.8% over the past three months. Given that the stock prices usually follow...